FeesSafety
Pluang+

Ionis cuts TRYNGOLZA sales forecast by half; shares plunge amid legal probe.

Market News
16 Nov 2026, 17:01 WIB
PRNewsWire
View Source
Bearish
Ionis cuts TRYNGOLZA sales forecast by half; shares plunge amid legal probe.

Ionis Pharmaceuticals reported a sharp drop in third-quarter TRYNGOLZA sales to $9.3 million from $31.8 million a year earlier, leading to a halving of its full-year sales forecast to about $50 million from $100-$110 million. Despite beating revenue and earnings estimates, shares fell over 25% after the announcement. Levi & Korsinsky is investigating potential securities law violations related to allegedly misleading statements about TRYNGOLZA's performance, encouraging shareholders who lost money to submit their information for a free review. Investors who bought shares at inflated prices may be eligible for compensation, with no upfront cost or court appearances required to participate in the investigation.

Following the news about Ionis Pharmaceuticals' sales and investigation, the stock shows resilience on Pluang, trading at USD 29.61 with a 1-day gain of 1.89% as of Nov 16, 2026 22:11 WIB. Despite recent challenges, the market cap stands at $4.84 billion, with the stock price closer to its 52-week low of $27.31 than its high of $86.50. Typical hold time for IONS on Pluang is 5 days, indicating relatively short-term investor interest.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App